var data={"title":"Quadrivalent meningococcal polysaccharide conjugate (TT) vaccine (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Quadrivalent meningococcal polysaccharide conjugate (TT) vaccine (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/724150?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=quadrivalent-meningococcal-polysaccharide-conjugate-tt-vaccine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Quadrivalent meningococcal polysaccharide conjugate (TT) vaccine (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668578\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Nimenrix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668581\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668608\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal disease prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> Adults &le;55 years: IM: 0.5 mL as single dose. <b>Note:</b> The need for a booster dose has not been established. Manufacturer labeling suggests that a second dose may be considered for patients at increased risk of exposure to meningococcal serogroup A and who received the first Nimenrix dose &gt;1 year prior.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations (NACI 2012):</i> <b>Note:</b> Based on limited evidence and expert opinion, use in high risk  individuals &ge;56 years of age is considered appropriate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Healthy individuals (&le;24 years of age): IM: 0.5 mL as a single dose even if the individual has previously been vaccinated as an infant or toddler; dose should be limited to those not revaccinated as a child &ge;12 years or adolescent.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-risk with underlying medical conditions and not previously immunized with quadrivalent conjugate meningococcal vaccine: IM: 0.5 mL dose; administer a total of 2 doses at least 8 weeks apart or at least 4 weeks apart when more rapid immunization is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Travel to high risk areas and not previously immunized with quadrivalent conjugate meningococcal vaccine: IM: 0.5 mL dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postexposure management (close contacts) or outbreak control (off-label use) (NACI 2012):</b> Recommendations dependent on meningococcal serogroup involved: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serogroup C:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previously unvaccinated: IM: 0.5 mL/dose immediately after exposure (monovalent or quadrivalent vaccine may be used)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previously vaccinated: IM: If vaccinated at &lt;1 year of age or if at high risk for invasive meningococcal disease due to underlying medical condition, re-vaccinate with 0.5 mL/dose if &ge;4 weeks since last dose; otherwise re-vaccinate if at least 1 year since last dose (monovalent or quadrivalent vaccine may be used)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serogroup A, Y, or W-135:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previously unvaccinated: IM: 0.5 mL/dose immediately after exposure; high-risk individuals with underlying medical conditions routinely require a total of 2 doses (administered at least 8 weeks apart or at least 4 weeks apart when more rapid immunization is needed)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Previously vaccinated: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If previously vaccinated with only monovalent conjugate meningococcal group C vaccine (Men C-C), administer 0.5 mL/dose (quadrivalent vaccine) immediately after exposure, regardless of when Men C-C was given</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If previously vaccinated with quadrivalent vaccine at &lt;1 year of age or if at high risk for invasive meningococcal disease due to underlying medical condition, re-vaccinate with 0.5 mL/dose (quadrivalent vaccine) if &ge;4 weeks since last dose; otherwise re-vaccinate if at least 1 year since last dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990771\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987922\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668596\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal disease prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary immunization:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants 6 to 12 weeks of age: IM: 0.5 mL at 2 and 4 months of age (may start as early as 6 weeks of age)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;1 year of age and Adolescents: IM: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Booster immunization: IM: For infants who have completed the primary immunization 2-dose series, administer 0.5 mL as a single dose at 12 months of age. <b>Note: </b>The need for a booster dose in individuals primed with a single dose at &ge;12 months of age has not been established. Manufacturer labeling suggests that a booster dose may be considered for patients at increased risk of exposure to meningococcal serogroup A and who received the first Nimenrix dose &gt;1 year prior.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations (NACI 2012):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years of age and Adolescents: Healthy individuals: IM: 0.5 mL as a single dose administered routinely at 12 years of age, even if the individual has previously been vaccinated as an infant or toddler.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;2 years of age and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High-risk with underlying medical conditions and not previously immunized with quadrivalent conjugate meningococcal vaccine: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Travel to high risk areas and not previously immunized with quadrivalent conjugate meningococcal vaccine: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postexposure management (close contacts) or outbreak control (off-label use) (NACI 2012):</b> Recommendations dependent on meningococcal serogroup involved:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serogroup C: Children &ge;11 years of age and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serogroup A, Y, or W-135: Children &ge;2 years of age and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159395\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159396\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668604\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nimenrix: 5 mcg each of polysaccharide antigen groups A, C, Y, and W-135 [bound to tetanus toxoid 44 mcg] per 0.5 mL dose [prefilled syringe containing diluent included]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668603\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668600\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: For IM injection only. Administer into the anterolateral thigh in infants and the anterolateral thigh or deltoid area in children (&ge;1 year of age), adolescents, and adults. Do not administer intravascularly, intradermally, or subcutaneously. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668584\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal disease prevention:</b> Provides active immunization against invasive meningococcal disease caused by <i>Neisseria meningitidis</i> serogroups A, C, Y, and W-135 in individuals 6 weeks to 55 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The National Advisory Committee on Immunization (NACI) recommends:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Routine vaccination</b> with a monovalent or quadrivalent conjugate meningococcal vaccine in healthy children &ge;12 years, adolescents, and young adults &le;24 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vaccination of high risk individuals:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents and young adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Laboratory workers routinely exposed to isolates of <i>N. meningitidis</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Military recruits</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons traveling to areas with high rates of endemic meningococcal disease or transmission. Use of a monovalent vaccine may not be appropriate based upon the serogroup prevalence in the region of travel.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons with congenital complement, properdin, factor D or primary antibody deficiencies or with acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons with HIV particularly if congenitally acquired</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persons with anatomic or functional asplenia, including sickle cell disease</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Based on limited evidence and expert opinion, NACI considers vaccination with quadrivalent conjugate meningococcal vaccine appropriate in individuals &ge;56 years of age who are at high risk of meningococcal disease due to travel to high risk areas or underlying medical conditions (NACI 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postexposure management:</b> NACI recommendations for persons considered to be at an increased risk for meningococcal disease:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chemoprophylaxis and immunoprophylaxis:</i> Selection of meningococcal vaccination to be based upon serogroup(s):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Individuals living in the same household, share sleeping arrangements, or with close contact (eg, kissing, shared cigarettes, shared eating or drinking utensils) of infected patient</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Employees and children of nursery schools or day care</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">See NACI guidelines for specific drug treatment at http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-meni-eng.php#a4.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46204130\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Postexposure management (close contacts) or outbreak control of meningococcal disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24743944\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Irritability (infants: 52% to 63%; children: 15% to 41%), drowsiness (infants: 36% to 53%; children: 14% to 28%), fatigue (12% to 29%), headache (16% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (infants: 33% to 38%; children: 11% to 23%), gastrointestinal symptoms (&le;15%; includes diarrhea, nausea, vomiting)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (19% to 51%), erythema at injection site (infants &amp; children: 25% to 43%; adolescents &amp; adults: 9% to 26%), swelling at injection site (infants &amp; children: 12% to 30%; adolescents &amp; adults: 8% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&ge;38&deg;C: 4% to 9%, infants: 23% to 32%; &gt;40&deg;C: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Hematoma at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Crying, dizziness, erythema, hypoesthesia, induration at injection site, injection site reaction, insomnia, injection site pruritus, limb pain, local anesthesia (injection site), malaise, myalgia, pruritus, skin rash, swelling of injected limb, warm sensation at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668588\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any component of the vaccine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668589\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]; NACI 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone vaccination in patients with an acute severe febrile illness. Consider deferring administration in patients with moderate illness. Vaccination should not be delayed for patients with mild acute illness (with or without fever) (NACI 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from IM administration. If the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Use with caution in terminal complement deficiencies, functional or anatomic asplenia, and severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For intramuscular injection only. Not intended for intravascular, intradermal, or subcutaneous administration. Confers protection only against <i>Neisseria meningitidis</i> serogroups contained in the vaccine. May be administered to patients previously vaccinated with a plain polysaccharide meningococcal vaccine; administration in patients previously vaccinated with a conjugated meningococcal C vaccine has not been studied. Vaccine contains tetanus toxoid but is not a substitute for tetanus immunization. NACI recommends use of monovalent conjugate C, quadrivalent, or multicomponent meningococcal vaccine in healthy individuals and use of a quadrivalent conjugate or multicomponent meningococcal vaccine in high-risk individuals (NACI 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Compared with other meningococcal serogroups, a more rapid decline of antibodies to meningococcal serogroup A has been observed in some clinical trials. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674144\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24674141\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=95152&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetanus Toxoids Vaccines: Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine may diminish the therapeutic effect of Tetanus Toxoids Vaccines.  Management: When possible, administer the meningococcal polysaccharide (groups A / C / Y and W-135) tetanus toxoid conjugate vaccine either together with or at least one month before a tetanus toxoids-containing vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668585\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were not observed in animal reproduction studies. According to the NACI, the use of conjugated meningococcal vaccines should be considered in pregnant women in circumstances such as travel to high risk areas or if indicated as postexposure prophylaxis against a vaccine preventable strain or during an outbreak (NACI 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668587\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if this vaccine is found in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. According to the NACI, inactivated vaccines, such as conjugate or multicomponent meningococcal vaccines, may be administered to women who are breastfeeding (NACI 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668602\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for syncope for at least 15 minutes following administration (ACIP [Kroger 2017]; NACI 2013). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24668593\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Induces immunity against meningococcal disease via the formation of bactericidal antibodies directed toward the polysaccharide capsular components of <i>Neisseria meningitidis</i> serogroups A, C, Y and W-135.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24799729\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Nimenrix (AE, AT, AU, BE, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, IE, IL, IS, LB, LT, LU, MT, NL, NO, PL, PT, QA, SE, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Canadian National Advisory Committee on Immunization (NACI). Canadian Immunization Guide, 2012. http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-eng.php. Accessed January 13, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian National Advisory Committee on Immunization (NACI). Canadian Immunization Guide, 2013. http://www.phac-aspc.gc.ca/publicat/cig-gci/p01-07-eng.php#post. Accessed January 13, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dbaibo G, El-Ayoubi N, Ghanem S, et al. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial. <i>Drugs Aging</i>. 2013;30(5): 309-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-polysaccharide-conjugate-tt-vaccine-united-states-not-available-drug-information/abstract-text/23494214/pubmed\" target=\"_blank\" id=\"23494214\">23494214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nimenrix (meningococcal polysaccharide groups A,C,W-135, and Y conjugate vaccine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-polysaccharide-conjugate-tt-vaccine-united-states-not-available-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-polysaccharide-conjugate-tt-vaccine-united-states-not-available-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 95152 Version 45.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F24668578\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F24668581\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F24668608\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990771\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987922\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F24668596\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51159395\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51159396\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F24668604\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F24668603\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F24668600\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F24668584\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F46204130\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F24743944\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F24668588\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F24668589\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F24674144\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F24674141\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F24668585\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F24668587\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F24668602\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F24668593\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F24799729\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/95152|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=quadrivalent-meningococcal-polysaccharide-conjugate-tt-vaccine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Quadrivalent meningococcal polysaccharide conjugate (TT) vaccine (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}